BioMarin Pharmaceutical will seek expanded approval for its bone growth-stimulating drug Voxzogo after the shot improved growth speed in children with a form of short stature, the company said Wednesday.
May 21, 2026 10:31 AM EDT
BioMarin to seek further approval of Voxzogo in form of short stature
Elizabeth Cairns
Senior biopharma journalist
BioMarin Pharmaceutical will seek expanded approval for its bone growth-stimulating drug Voxzogo after the shot improved growth speed in children with a form of short …
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA…
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a…
